Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthFRA:8RK 56 EV-to-EBIT is 11.87 as of Aug. 25, 2026, which is 35% above its 10-year median of 8.77. GuruFocus rates FRA:8RK with a GF Score™ of 56/100 and a GF Value™ of €3.53 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Labiana Health ranks better than 62.17% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Labiana Health's Enterprise Value for the quarter that ended in Dec. 2025 was €61.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €7.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health EV-to-EBIT Related Terms
Labiana Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Labiana Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Labiana Health's EV-to-EBIT falls into.
Labiana Health's current Enterprise Value is €84.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €7.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (FRA:8RK) has a EV-to-EBIT of 11.87 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labiana Health and its competitors. This is 35% above median its historical median of 8.77. According to the industry distribution chart, Labiana Health ranks #261 out of 690 companies in the Drug Manufacturers industry, placing it in the top 37.8%.
Is Labiana Health's EV-to-EBIT too high?
Labiana Health's current EV-to-EBIT of 11.87 is 35% above median its 10-year median of 8.77. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Labiana Health's value of 11.87 is 24.9% below this industry median. Based on the distribution chart, Labiana Health ranks #261 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #261 out of 690 companies for EV-to-EBIT. This puts Labiana Health in the upper half of its industry. The industry median EV-to-EBIT is 15.81. Labiana Health's value of 11.87 is 24.9% below this benchmark. While the company's 10-year median is 8.77 vs. the industry median of 15.81, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current EV-to-EBIT of 11.87 is 24.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Labiana Health and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current EV-to-EBIT is 11.87, which is 35% above median its own 10-year median of 8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (FRA:8RK) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.53, compared to a current price of €6.15 — trading 74.2% above its estimated fair value. The current EV-to-EBIT is 11.87, which is 35% above median its 10-year median of 8.77 and 24.9% below the Drug Manufacturers industry median of 15.81. Labiana Health's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Labiana Health (FRA:8RK), the current EV-to-EBIT is 11.87 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (FRA:8RK) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.15 is trading 74.2% above its estimated GF Value™ of €3.53.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for FRA:8RK:
EV-to-EBIT: 11.87 (35% above median its 10-year median of 8.77)
GF Value™: €3.53 vs. price of €6.15 (74.2% above fair value)
Industry Position: 24.9% below the Drug Manufacturers median (#261 of 690)
No single metric tells the full story. See the FRA:8RK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
56GF Score
Get the complete analysis for FRA:8RK
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8RK has been successfully added to your 
